A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
Phase 1
Recruiting
- Conditions
- Chronic Weight Management
- Interventions
- Drug: ASC47 +SemaglutideDrug: Placebo+Semaglutide
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Ascletis Pharma (China) Co., Limited
- Target Recruit Count
- 24
- Registration Number
- NCT06972992
- Locations
- 🇺🇸
Ascletis Clinical Site, San Antonio, Texas, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Ascletis Pharma (China) Co., Limited
- Target Recruit Count
- 72
- Registration Number
- NCT06680440
- Locations
- 🇺🇸
Ascletis clinical site, Salt Lake City, Utah, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
Phase 1
Recruiting
- Conditions
- Chronic Weight Management
- Interventions
- Drug: ASC30 Injection, for subcutaneous use or placebo
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Ascletis Pharma (China) Co., Limited
- Target Recruit Count
- 115
- Registration Number
- NCT06679959
- Locations
- 🇺🇸
Ascletis clinical site, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath